Determination of serum myoglobin by the reverse passive hemagglutination assay (RPHA) and radioimmunoassay (RIA)

Serum myoglobin (Mb) is an important biological marker in the early diagnosis of the acute myocardial infarction (AMI). In a previous paper we showed that RPHA, which consists in the agglutination of anti-Mb antibody--coated erythrocytes by solutions containing Mb, is a simple, rapid and highly sensitive assay (approx. 1 ng/ml). 42 sera from AMI patients and 20 sera from healthy subjects were investigated by RPHA. The geometric mean (x/divided by SD) of serum Mb titers in AMI patients was 362 x/divided by 3.94, in the range of 64-8192 (the reciprocal dilutions) and in normal sera was 19 x/divided by 1.36, in the range of 16-32. The difference between the mean values was statistically significant at p < 0.001. Subsequently, serum Mb concentration was determined by RPHA and RIA in 51 AMI sera prelevated at various stages of the disease. A high degree of correlation was found between the two methods. Log Y (RPHA titers) = -0.9174 + 1.5879 log X (RIA); ESE: +/- 0.1947; r = 0.9601. In four AMI patients successive determinations were made at every 6 hours: serum Mb curves determined by RPHA and RIA had a parallel evolution and this was an additional argument for the validation of RPHA. Being quite simple and easy of execution RPHA is the most suitable method by which an early AMI diagnosis can be made.